What is it about?

In our study, we develop an algorithm to identify statistically different treatment utilization patterns not only between health systems but also among individual providers within health systems. We demonstrate the utility of this framework in combination with a existing risk stratification tools such as the Framingham Cardiovascular Risk Score to identify differences in utilization of diabetic medications with known cardioprotective benefits for patients with high cardiovascular disease risk.

Featured Image

Why is it important?

Using the newly created University of California Health Data Warehouse, we present the first study to analyze antihyperglycemic treatment utilization across the five large University of California academic health systems (Davis, Irvine, Los Angeles, San Diego, and San Francisco) including 97,231 type 2 diabetes patients from 1,003 UC-affiliated clinical settings. Our work demonstrates the power of EHRs to quantify differences in treatment utilization, a necessary step towards standardizing precision care for large populations.


Beyond the context of treatment intensification, insights obtained using our novel statistical framework hold promise to organize, standardize, and thus improve institution-wide care management for type 2 diabetes and other diseases where there exists a wide diversity of pharmacologic treatment choices and guidelines. As EHRs spread in use and data availability, these types of analyses will become more powerful and useful to clinicians, providers, and payers.

Thomas Peterson
University of California San Francisco Parnassus Library

Read the Original

This page is a summary of: Quantifying Variation in Treatment Utilization for Type 2 Diabetes Across Five Major University of California Health Systems, Diabetes Care, February 2021, American Diabetes Association,
DOI: 10.2337/dc20-0344.
You can read the full text:




The following have contributed to this page